Germany – Regional Perspectives on the Management of Patients With R/R CLL/SLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
Italy—Regional Perspectives on the Management of Patients With R/R CLL/SLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
France—Regional Perspectives on the Management of Patients With R/R CLL/SLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
US - Regional Perspectives on the Management of Patients With R/R CLL/SLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
BTK Degrader Bexobrutideg in Patients With Relapsed/Refractory CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Second-line Pirtobrutinib in CLL/SLL After Covalent BTKi Treatment: A Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
CaDAnCe-101 Phase I Study of the BTK Degrader BGB-16673 in R/R CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Final Analysis of the Phase I/II BRUIN Trial of Pirtobrutinib in Patients With CLL/SLL Previously Treated with a Covalent BTKi    

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25
ALPINE Long-term Extension Study of Zanubrutinib in Relapsed or Refractory CLL/SLL

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

Content Format:

Podcast Episodes

Credit Type:

AMA

Credits:

0.50
Understanding BTK Inhibitor Resistance in CLL

Content Format:

Slideset

Credit Type:

--

Credits:

--
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies

Content Format:

Video

Credit Type:

AAPA | ANCC

Credits:

1.00
Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Cases in CLL: Second-Line Therapy Following Chemoimmunotherapy

Content Format:

Multimedia

Credit Type:

AANP | ACPE | AMA

Credits:

0.25